Transgender health: Hormone therapy may raise risk of CV events
From AHA 2018, an analysis gives clue to how empagliflozin cuts cardiovascular risk, and study findings challenge cholesterol guidelines for patients with type 1 diabetes. Also, we take a closer look at how smoke-free policies affect blood pressure, and how magazine-ranked “Best Hospitals” actually perform.
Subscribe to Cardiocast wherever you get your podcasts.Amazon AlexaApple Podcasts
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.